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Objective. The aim of this study was to assess the mid term effect of proximal bare metal fixation design on renal function
in patients undergoing endovascular repair (EVR) of abdominal aortic aneurysm (AAA).
Methods. Consecutive EVR patients for AAA from December 1995-2001 were included and grouped to either infrarenal
(Group 1) or uncovered suprarenal (Group 2) fixation. Peri-operative renal function and at 6, 12 and 24 months was
determined by serum creatinine (sCr mmoll1) and Cockroft-Gault creatinine clearance (CrC mlmin1). Changes in renal
function were compared using non-parametric analysis.
Results. Of the 179 EVR procedures during this six-year period, paired renal data was available for 135 patients at a min-
imal follow-up of 6 months (Gp1, n¼ 63; Gp2, n¼ 72). Median pre-EVR sCr and CrC were 113, 57 in Group 1 and 108,
58 in Group 2, p¼NS. There was no significant deterioration in renal function within or between either group at 2 years
post-EVR: median sCr, CrC values were 118, 56 (Group 1) and 111, 56 (Group 2), all p¼NS.
Conclusion. This study suggests mid-term renal function remains unaffected following EVR of AAA, irrespective of prox-
imal fixation type. Designs to improve stent durability and EVR applicability do not appear to compromise renal function.
Keywords: AAA repair; Endovascular repair; Renal function; Suprarenal fixation; Transrenal fixation; Stenting.Introduction
A specific adaptation designed to improve the suspect
long-term durability of early endografts1,2 for AAA
repair has been the addition of an uncovered bare
metal stent to allow supra-renal fixation.3e5 There
are a few potential advantages of this EVR device
scheme. Firstly, an enhanced seal may be achieved
in native non-aneurysmal supra-renal aortic tissue, re-
ducing the chance of late failure due to device migra-
tion and proximal endoleak.6,7 This is of particular
importance in view of published concern regarding
continued infra-renal neck dilatation post-EVR.8e10
Secondly, these endografts may in fact improve pa-
tient eligibility for EVR in cases of adverse neck mor-
phology, since less infra-renal neck is required to
generate an adequate seal.11,12
The deployment of bare metal stents across the re-
nal artery ostia raises concern regarding subsequent
kidney function. Review of the current literature
would suggest that this practice is safe at least in the
short-term,6,12e24 but little data exists to confirm this
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to examine our own EVR experience and assess the
consequence of SR-fixation on delayed renal function.
Patients and Methods
One hundred and seventy-nine consecutive patients
undergoing EVR for AAA at a single centre over
a six-year period (December 1995-December 2001)
were identified from a prospectively maintained en-
dovascular database. All case-notes were reviewed
and patients alive between 6 months and 2 years
post-EVR were recalled.
Patients’ sex, age, weight, AAA size (maximal
antero-posterior CT projection) and renal function
were recorded both pre- and post-operatively (peak
value) and at each subsequent follow-up interval of
6, 12 and 24 months. Procedural variables included
device type and radiological contrast load. In order
to assess any renal effect of fixation-type, the series
was divided into two groups depending upon
whether they had received infra-renal (IR, Group 1)
or suprarenal fixed devices (SR, Group 2). Supra-renal
fixation was defined as the presence of a bare-metal
stent segment across both renal artery ostia with
a proximal seal generated in the native supra-renalrved.
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was based primarily on endograft availability at the
time of AAA repair, with the IR devices tending to
be implanted prior to the availability of the SR de-
vices. In other words, the two study groups were vir-
tually consecutive in chronology with the earlier EVR
cases almost exclusively Group 1 (IR) and the latter
patients receiving Group 2 devices (SR).
Assessment of renal function was based on the clin-
ically used biochemical marker of serum creatinine
(sCr/mmoll1). Paired renal data was available for 135
patients from the entire series at a minimal follow-up
time of 6 months. Serum creatinine samples were ana-
lysed on an Olympus 2700 multi-channel analyser
(Jaffe´ reaction-based) using the manufacturers sup-
plied reagents (Olympus Instruments, London), pro-
viding a between-batch imprecision of less than 2%
for each analyte. Creatinine clearance (CrC/mlmin1)
values were then derived using the well validated
Cockroft-Gault formula25 with a gender correction fac-
tor (multiplication by 0.85) applied for female patients.
Data Analysis
All study information was anonymised and stored
within a Microsoft Excel (Microsoft Ltd., Reading,
UK) spreadsheet. Relevant data was exported to Mini-
tab Version-13 for Windows (Minitab Inc., PA, USA)
software package for statistical and graphical analy-
sis. Unless indicated, median values are quoted for
continuous variables. Presentation of renal data is by
means of serial box-and-whisker plots.
Observational comparisons with non-continuous
data were made using the chi-square test (c2). The
one-sample Wilcoxon test was used to compare
paired non-parametric continuous variables (i.e.
within group) and Mann-Whitney U-test for 2-sample
(i.e. between group) non-parametric analysis. A Bon-
ferroni correction factor was applied in both tests for
repeated observations. Results were considered statis-
tically significant if p< 0.05. The term ‘NS’ denotes not
statistically significant.
Results
One hundred and seventy-nine patients underwent
EVR for AAAwithin the six-year study period. Eighty-
seven cases were IR-fixed stents (Group 1) and the
remaining 92 patients had SR-fixed devices (Group 2).
Pre-operative status
Group-specific patient demographics, aneurysm size
and pre-operative renal function (sCr and CrC) forthe entire series are shown in Table 1. The age range
and sex distribution of the study limbs were analo-
gous. The aneurysms of Group 2 were significantly
larger than those repaired with infra-renally fixed
devices ( p¼ 0.001).
Thirty-eight patients (Group 1, n¼ 23; Group 2,
n¼ 15, p¼NS) were noted to have occult renal impair-
ment indexed by a serum creatinine> 130 mmoll1
pre-operatively. No patients were receiving renal
replacement therapy (RRT) pre-EVR.
Early outcome & Renal function
Stent deployment was technically successful in all
cases with no intra-operative deaths. Endograft type
for both groups is summarized in Table 2. Contrast
load during EVR was significantly higher in Group
1 (median 300 ml, range 100e900 ml) as opposed to
the later Group 2 cases (median 230 ml, range 110e
800 ml, p ¼ 0.01). The procedural mortality (both in-
hospital and 30-day) for the entire series was 4.5%
(8 of 179 cases). Fixation-specific EVR mortality
was not significantly different: 5.7% for Group 1
(5/87; 3 Vanguard & 2 Talent devices) and 3.3% for
Group 2 (3/92). Apart from one fatal CVA in a pa-
tient receiving a Vanguard device, the documented
cause of death in all other cases was myocardial
infarction.
No significant difference in sCr was detected post-
EVR to either corresponding pre-operative values or
between the two groups. Using the Cockroft-Gault
formula, group specific CrC values were calculated
as a surrogate estimate for GFR in the peri-operative
phase. Again, there was no significant difference in
CrC either within, or between the groups pre and
post-operatively (see Fig. 1).
Table 1. Pre-EVR demographic factors & renal function
Group 1 (IR) Group 2 (SR)
Age (years)
Median 73 74
Range 56e87 56e90
Sex (M:F) 78:9 82:10
AAA diameter (mm)
Median 60 65*
IQR 55e70 58e78
Range 45e145 41e100
sCr (mmoll1)
Median 113 108
Range 72e243 75e307
CrC (mlmin1)
Median 57 58
Range 22e102 22e139
* ( p< 0.05)Eur J Vasc Endovasc Surg Vol 32, November 2006
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early post-operative period was required by 2 patients,
one from each group. In Group 1, a patient with a func-
tionally impaired single kidney (pre-operative sCr
243 mmoll1) became anuric post-EVR with estab-
lished renal failure reflected by a peak sCr of
461 mmoll1. After temporary CVVH in the initial
post-operative period, he returned to his pre-operative
renal state with 12-month sCr value of 264 mmoll1.
In Group 2, a patient with pre-existing diabetic ne-
phropathy required RRT post-operatively following
the development of acute-on-chronic renal failure
(pre-operative sCr 206 mmoll1; post-operative sCr
630 mmoll1). This was precipitated by a peri-operative
myocardial infarction with subsequent cardiogenic
shock and multi-organ failure. The patient died six
days post-EVR.
Inadvertent single renal artery occlusion occurred
during stent deployment in two EVR procedures
(both Group 2). This insult was reflected in higher
post-EVR peak sCr measurements of 125 and
142 mmoll1 (pre-operative sCr: 91 and 96 mmoll1 re-
spectively). Nevertheless at 24-month follow-up, no
RRT had been necessary in either patient.
Table 2. Group-specific EVR devices
Device Type Group 1 (IR) Group 2 (SR)
Vanguard (Boston Scientific) 49 e
Talent (WMC/Medtronic) 13 e
Excluder (Gore) 8 e
Endologix (Powerlink) 5 e
Other (AneuRx, EVT, Mintec) 12 e
Zenith (Cook) e 92
Total 87 92
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Fig. 1. Peri-EVR Creatinine Clearance (all p¼NS). Boxes
represent the inter-quartile range and connect bar indicates
median value. Whiskers define the 90% range. Statistical
analysis by the 1-sample Wilcoxon (within group) and
Mann Whitney (between group) tests with Bonferroni
correction.Eur J Vasc Endovasc Surg Vol 32, November 2006Mid-term renal function
Of the 179 cases included in the study, paired renal
data was available for 135 patients at a minimal fol-
low-up time of 6 months (Group1, n¼ 63; Group 2,
n¼ 72). Omitted patients had either died within 6
months of EVR (n¼ 16), lost to follow-up (n¼ 11) or
were not reviewed nor blood sampled at a correct
time interval post-EVR (n¼ 17).
At 6, 12 and 24-month review, patients of both
Groups had no significant elevation in sCr compared
to their pre-operative status (see Fig. 2). Similarly,
there was no difference between the IR and SR groups
at each follow-up time interval. Group specific mid-
term creatinine clearance following EVR is illustrated
in Fig. 3. CrC remained remarkably constant over the
2-year study, regardless of fixation type. Comparison
of these GFR estimates between both study limbs at
each defined time-point confirmed no significant dif-
ferences in delayed CrC post-EVR.
There were 3 cases of evolving chronic renal failure
post-operatively in the series. The Group 1 case con-
cerned a patient who received a Vanguard device
and was noted to have an increasing sCr over the first
year’s follow-up (pre-op sCr 129 mmoll1, 12-month
sCr 212 mmoll1) in the absence of other renal disease
processes. A renal biopsy was performed which
revealed evidence of cholesterol embolization, most
likely as a complication of EVR. At last review the
patient was clinically well and not requiring RRT. In
Group 2, one patient with recognized diabetic ne-
phropathy (pre-EVR sCr 235 mmoll1) was found at
first annual follow-up to have a sCr of 318 mmoll1.
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Fig. 2. Fixation Specific Late Serum Creatinine (all p¼NS).
Boxes represent the inter-quartile range and connect bar in-
dicates median value. Whiskers define the 90% range. Statis-
tical analysis by the 1-sample Wilcoxon (within group) and
Mann Whitney (between group) tests with Bonferroni
correction.
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but no evidence of renal artery stenosis was found.
The patient is currently under close review by the ne-
phrologists with no RRT. The other patient with a SR
device was commenced on haemo-dialysis 3 months
post-EVR for progressive renal dysfunction attributed
to known polycystic kidneys.
Discussion
The incidence of renal dysfunction post-EVR is re-
ported at approximately 6% and this is notably higher
in those patients with pre-operative renal impair-
ment.26 Although the exact cause of this complication
is unclear, implicated factors include radiological
contrast-associated nephropathy, renal artery trauma,
stent-induced stenosis and aortic neck thrombo-
embolism following vessel instrumentation and
manipulation.12,20 All of these features are generic to
EVR, irrespective of graft configuration.
Since the concept of uncovered supra-renal fixation
was first proposed, concern has naturally persisted
with respect to its potential additive adverse effect
on renal function. Preliminary laboratory studies
with animal models suggested that the placement of
bare metal stent struts across the renal artery ostia
was indeed safe at least in the short-term,27,28 and in-
troduction of the practice to man soon followed.
The Lund Group published the earliest report of re-
nal outcome following SR-fixed EVR in humans in
1997. In this study, 18 patients underwent EVR of
AAA with deliberate Gianturco Z-stent deployment
across one or both renal artery ostia to improve graft
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Fig. 3. Fixation Specific Late Creatinine Clearance (all
p¼NS). Boxes represent the inter-quartile range and con-
nect bar indicates median value. Whiskers define the 90%
range. Statistical analysis by the 1-sample Wilcoxon (within
group) and Mann Whitney (between group) tests with Bon-
ferroni correction.durability. At median follow-up of 6 months, all of
the 25 stent-covered renal arteries remained patent
(imaged by spiral CT and angiography) and no eleva-
tion in the cohorts’ sCr was observed.13
Since this seminal paper, several independent
groups have addressed the issue of renal function fol-
lowing EVR with uncovered bare metal supra-renal
fixation (see Table 3).6,12,14e24,29 Despite varying bio-
chemical and radiological methods for analysis, there
is currently no evidence suggesting that these endog-
rafts are associated with any clinically significant
renal compromise.
In this retrospective study we compared the renal
outcome in patients undergoing EVR with devices uti-
lizing either IR or SR fixation by serial measurement
of the biochemical markers sCr and Cockroft-Gault
formulated CrC. We acknowledge the physiological
and analytical limitations of sCr methods,30,31 but
their measurement permits an appraisal of renal ex-
cretory function, which is generally accepted as the
best clinical estimate of functional renal mass.32,33 Fur-
thermore, it is these indices of kidney function that
tend to be routinely used in daily clinical practice.
The two study limbs were comparable in terms of
age, sex distribution and pre-operative renal func-
tion. No patient in either group required renal re-
placement therapy pre-operatively. The significantly
larger aneurysms of Group 2 reflected both the
non-randomized nature of the study and the chrono-
logical fact that the first SR device at our institution
was not deployed until September 1998, nearly 3
years (and 60 IR devices) after our EVR program
had commenced. As a result, Group 2 patients had
the benefits of clearer AAA management guide-
lines,34 latest device technology and finally the con-
siderable accrued procedural experience of the EVR
team i.e. a completed learning curve. The decision re-
garding the nature of device used (i.e. infrarenal or
suprarenal) was dependant on both the aneurysms’
morphological suitability determined by contrast-
enhanced CT scanning and the commercial availability
of specific suitable devices at the time of implanta-
tion. Patients were not randomized in this study to
one specific treatment limb, rather to the most clini-
cally appropriate, cost-effective stent available to
them at that particular time.
Although the recently published UK EVAR and
Dutch DREAM trials reported a more favourable
early survival,35,36 this particular series included those
patients pre-dating EVAR trial recruitment (com-
mencing early 1999) and also higher-risk individuals
who may with hindsight have been better managed
conservatively. In spite of this, no deaths were docu-
mented as directly due to an acute renal cause.Eur J Vasc Endovasc Surg Vol 32, November 2006
520 P. Davey et al.Table 3. Summary of Renal studies post Supra-renal EVR
Year Number
of SR-EVR
Mean/Median
Follow-Up
(months)
Renal Assessment No. IR ‘controls’ Ref.
Biochemical Radiological
Malina et al. 1997 18 6 sCr Spiral CT e 13
Angiography
Marin et al. 1998 37 10.3 sCr CT e 6
Duplex
Angiography
Kichikawa et al. 2000 18 14 BUN CT e 16
sCr Duplex
Bove et al. 2000, 2003 28, 37 6, 29 BUN Duplex e 18,22
sCr CT Angiography
Lobato et al. 2000 35 11 sCr CT e 15
Duplex
Izzedine et al. 2002 39 6, 30 sCr Renal Tomography e 19
CrC (Cockroft-Gault)
Kramer et al. 2002 69 ‘overstented
renal arteries’
12 e Spiral CT ‘124 uncovered
arteries’
14
Mehta et al. 2004 111 19 sCr CT 385 23
CrC (Cockroft-Gault)
Alric et al. 2003 169 30 sCr e 146 17
Cayne et al. 2003 69 17 sCr Contrast enhanced CT 61 24
CrC (Cockroft-Gault)
Lau et al. 2003 32 12 sCr CT Angiography 57 12
Surowiec et al. 2004 60 23 sCr Contrast
enhanced CT
53 20
Grego et al. 2004 47 16 sCr 99Tc-DTPA e 21
Parmer et al. 2006 91 7.3 sCr CT Angiography 192 29
CrC (Cockroft-Gault)Analysis of sCr and CrC values suggest preserved
peri-operative and mid-term renal function, regard-
less of the presence or absence of uncovered bare
metal graft struts across the renal artery ostia. Despite
no formalized renal protection policy within the unit,
all those patients with ‘renal impairment’ (abnormally
elevated sCr in the absence of RRT) underwent careful
intravenous fluid optimization with routine urinary
catheterisation and central venous monitoring where
appropriate. If possible, the administration of any
contrast agent prior to EVR (within 2 weeks) was
avoided and the volume used during EVR was re-
stricted to the minimum required. Although it was
not the policy of this unit to routinely prescribe puta-
tive ‘reno-protective’ agents such as dopexamine or
mannitol, a peri-operative intravenous infusion was
commenced if clinically indicated. An additional
intra-operative measure taken to minimize renal
injury is the angiographic imaging of the renal arteries
following partial stent deployment. This permits con-
firmation of correct device positioning prior to com-
plete release in order to reduce the incidence of
renal artery occlusion by the covered segment of the
stent. The technique is not completely failsafe and
we observed two cases of deployment error in the
series (both Zenith devices) with cranial slip after im-
aging and subsequent single renal artery occlusion.
Fortunately, apart from an observed elevation in theEur J Vasc Endovasc Surg Vol 32, November 2006sCr of both cases there have been no other clinically
significant renal sequelae to this point.
In their series of 315 patients with a mean follow-up
of 30.1months, theNottingham group report renal out-
come following EVR for both ruptured and elective
AAA.17 Pre-EVR renal impairment was defined as
sCr> 130 mmoll1 and/or long-term dialysis. Signifi-
cant post-operative renal dysfunction was referred to
as a 20% increase in sCr from baseline in patients with
a ‘normal’ sCr pre-EVR and additional deterioration in
sCr in those with pre-operative renal impairment
(n¼ 69, 21.9%). They concluded that it was only the
presence of pre-operative renal failure and not the use
of SR fixation that was associated with the permanent
post-operative renal dysfunction detected in 9.2% of
EVR patients. Although not a formal sub-group analy-
sis, application of the Nottingham renal criteria to
our study reveals a comparable rate of pre-operative
renal impairment of 21.2% (38 of 179 cases with
sCr> 130 mmoll1 and none receiving long-term dialy-
sis). Post-EVR, wewould report amore favourable rate
of permanent renal impairment of 4.5% (8 cases) for the
entire series. Similarly, groupspecific renal failure is not
significantly different (Fisher exact test): 2.3% for
Group 1 (2/87) and 6.5% (6/92) for Group 2. These re-
sults are only slightly inferior to the 5% permanent re-
nal dysfunction rate reported by Izzedine et al.
following SR-EVR.19
521Effect of Bare Metal Suprarenal Fixation on Renal Function Following EVRMuch recent interest has focused on the potential
application of a low molecular weight protein, cysta-
tin C as a marker of renal function.37e42 It has been
validated by various gold-standard clearance analyses
that are inappropriate for routine clinical use, and
shown to be superior to sCr measurement in this
respect.43e46 Contrary to sCr, serum cystatin C levels
remain unaffected by the physiological variables of
sex, muscle mass and dietary intake.42 Finally and
most importantly, significant increases in serum cysta-
tin C have been reported with minimal, currently sub-
clinical mild GFR reduction, allowing a more sensitive
and possibly an earlier detection of renal dysfunction
than with sCr methods.42,47 In view of this, its mea-
surement in a prospective study assessing the poten-
tial silent renal injury following SR-EVR is proposed.
In conclusion, this present work adds further
supporting biochemical evidence that EVR in the
treatment of AAA is indeed safe for the kidneys to
mid-term follow-up. Furthermore, this preservation
of renal function is independent of proximal fixation
designs incorporating uncovered supra-renal fixation.
This modification in endograft design to improve both
the durability and applicability of EVR in AAA man-
agement is not apparently at the expense of mid-term
renal function.
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